Based on IGFBP2 positivity of breast cancers, a DNA vaccine was designed, encoding HER-2/neu, IGFBP2 and insulin-like growth factor 1 receptor (IGF1R) as tumor associated antigens and it proved to be effective in preclinical trials. Here, ERBB2 is linked to neoplasm.